Chemycal has been acquired by 3E
Learn MoreDiscover how Chemycal PRO helps you boosting your regulatory monitoring:
The highly anticipated ENDO 2023 conference saw experts engage in a spirited discussion on the merits and drawbacks of administering vitamin D supplements to women at risk of osteoporotic fractures. A notable session, titled "Is there a role for vitamin D supplementation for women at risk for osteoporotic fracture?", explored this topic, uncovering a pivotal debate in the realm of endocrinology. The discourse comes in the wake of the Vitamin D and Omega-3 Trial (VITAL) study's publication in the New England Journal of Medicine in 2019, which failed to show reduced cancer or cardiovascular disease risk due to vitamin D supplementation. Ghada El-Hajj Fuleihan from the American University of Beirut presented the "Pro side," highlighting discrepancies in previous research and advocating for a nuanced approach to evaluating data. On the "Con side," Steven R. Cummings of California Pacific Medical Center Research Institute argued for evidence-based conclusions and urged physicians to provide patients with accurate guidance. This debate serves as a catalyst for clarifying the role of vitamin D supplementation and its impact on osteoporotic fractures.
MORE INFO ON: endocrinenews.endocrine.org2013 © MyChemicalMonitoring. ALL Rights Reserved. About Us | Terms and Conditions